SCIENTIFIC REPORTS

OPEN

Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase

Rami S. Kantar^{1,2,*}, Ghazal Lashgari^{1,2,*}, Elie I. Tabet^{1,2}, Grant K. Lewandrowski^{1,2},
Litia A. Carvalho^{1,2} & Bakhos A. Tannous^{1,2}

Received: 28 May 2015

Accepted: 28 April 2016

Published: 20 May 2016

We developed a novel approach to assess tumor vascularity using recombinant *Gaussia* luciferase (rGluc) protein and bioluminescence imaging. Upon intravenous injection of rGluc followed by its substrate coelenterazine, non-invasive visualization of tumor vascularity by bioluminescence imaging was possible. We applied this method for longitudinal monitoring of tumor vascularity in response to the anti-angiogenic drug tivozanib. This simple and sensitive method could be extended to image blood vessels/vasculature in many different fields.

Tumorigenesis is associated with increased vascularity to maintain adequate supplies of oxygen and nutrients^{1–3}. Several anti-angiogenic therapies targeting tumor vascular moieties such as vascular endothelial growth factor (VEGF) receptor as well as integrins, for several tumor types have been established as a promising therapeutic approach^{4–6}. These therapies appear to be more cytostatic rather than cytotoxic, and therefore, are not desirably assessable with traditional imaging modalities that evaluate tumor volume⁷. As a consequence, adequate methods of assessing tumor vascularity and the response to anti-angiogenic therapeutics remain controversial⁸. Recent advancements in molecular imaging techniques have provided the possibility of noninvasive assessment of tumor response to different therapies. Several reports using MicroPET/CT imaging with different radiolabeled tracers to monitor anti-angiogenic therapies have been described^{9,10}. These tracers mostly target receptors on endothelial cells such as integrins. However, not all tumor types have predominantly high expression of integrins on endothelial cells, compared to tumor cells. For instance, melanoma tumors have been shown to have higher expression of a specific subset of integrins targeted with a tracer, as compared to the tumor vasculature¹¹. In case where radiotracers are conjugated with an intact antibody, clearance from blood is relatively slow leading to a high background accumulation⁹. Another potential limitation of this method is the distinction between tumors and inflammation might not be feasible due to similar intense uptake by both inflammatory lesions and malignancies¹². Fluorescence-based optical imaging methods have also been used to visualize tumor blood vessels. In this approach, vascular-specific fluorescent probes are synthesized by conjugating antibodies such as anti-VEGF antibody with a fluorescent dye^{13,14}. In contrast to microPET, fluorescence imaging does not require radioactive materials, and minimal tissue autofluorescence allows efficient photon penetration and subsequently enhanced target-to-background ratios¹⁴. More recently, Fab fragment of antibodies are used instead of intact antibodies to overcome the long half-life of high molecular weight, leading to accumulation in the liver¹⁵. One limitation for using fluorescence imaging is that accurate quantification of the results is challenging. Another caveat is the depth of the tissue that can be evaluated which restricts its clinical application to only superficial tumors¹⁶. This approach also relies on sophisticated and expensive instrumentation including multiphoton microscopy, fluorescence tomography and intravital imaging^{17,18}. In addition to these techniques, different MRI parameters such as contrast enhancement have been introduced as potential angiogenesis biomarkers¹⁹. Most of these parameters were found to be reflection of the physiological changes in tumor vascularity such as perfusion and permeability, rather than accurate measures of microvascular density. Therefore, contrast-enhanced MRI is more often used to assess the structural and hemodynamic status of solid tumors⁷. Vessel-caliber MRI on the other hand has emerged over the past decades as a potential method to monitor anti-angiogenic therapy in clinical trials^{20,21}. This approach takes advantage of the formation of abnormal tumor vessels with a wide spectrum of calibers in cancer tissue and quantifies the average vessel diameters and average vessel densities for arteries, capillaries and veins⁷.

¹Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. ²Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to B.A.T. (email: btannous@hms.harvard.edu)

Figure 1. Optimization of rGluc assay to image tumor vascularity. (a) Increasing number of U87 cells or PBS (control) were implanted in nude mice ($n = 4$). Two weeks later, mice were injected with rGluc followed by coelenterazine and imaged using a CCD camera. Gluc signal in photons/min (p/min) for different tumor sizes is indicated. Overlay of light with bioluminescence (top) or pseudocolor (bottom) images are shown. (b–d) Tumor-bearing mice ($n = 3$) were injected with rGluc followed by coelenterazine retro-orbitally and images were acquired every minute over 10 minutes. Average % of total photon flux (where first minute is set at 100%) $\pm$ SD is plotted (b). Bioluminescence imaging from a representative mouse with tumor-associated signal at every time point is shown (c). Bioluminescence images of mice with different tumor sizes are shown at different time points (d). (e) Gluc-based bioluminescence imaging of tumor vascularity as well as Fluc imaging (for tumor volume) was performed for small, large and necrotic tumors; showing an H&E staining of the necrotic tumor; scale bar 200 μ m. (f) Repeated imaging of the same mice at four different time points over 24 hrs with standard deviation (SD) presented for each mouse ($n = 3$). Representative bioluminescence images from mouse 2 are shown in the upper panel.

Although a correlation between tumor vascular status, tumor grade and response to therapies has been found in several studies^{22–24}, the complex process of image acquisition in vessel-caliber MRI justifies the limited attention this technique has received²⁵.

Bioluminescence imaging on the other hand has the advantage of simplicity with negligible background signal^{26,27}. It relies on production of light, following a chemical reaction in which the enzyme (luciferase) oxidizes a substrate leading to photon emission. Typically, cells of interest are engineered *ex vivo* to express the luciferase reporter under the control of a constitutive or tissue/process-specific promoter, then implanted into the animal and tracked non-invasively upon injection of the corresponding substrate^{26,28–30}. Recently, we and others have shown that the naturally secreted *Gaussia* luciferase (Gluc) could be used for quantitative assessment of different biological processes in mice by measuring its level in microliters of blood *ex vivo*^{28,31–34}. Gluc is the smallest luciferase cloned (19.9 kDa) and is thermostable, making it very suitable for different applications. Given the advantages of this luciferase, we evaluated here the potential use of recombinant Gluc protein (rGluc) in combination with its substrate coelenterazine, for noninvasive and real-time imaging of tumor vascularity in small animals.

Results and Discussion

We first designed an *in vivo* rGluc-based bioluminescence assay for non-invasive imaging of tumor vascularity. We implanted different numbers of U87 human glioblastoma cells subcutaneously into the flanks of nude mice. Two weeks post-implantation, when tumors reached different sizes, we visualized tumor vascularity by *in vivo* bioluminescence imaging after intravenous (i.v) injection of recombinant Gluc (rGluc; 10 mg/kg body weight) followed by its substrate coelenterazine (5 mg/kg body weight) and acquisition of photon counts for 1 minute using a cooled charge-coupled device (CCD) camera. The captured signal intensity positively correlated with tumor size, number of implanted cells, and clear visualization of tumor vascularity (Fig. 1a). Furthermore, we could visualize all mice blood vessels, especially in control animals with no tumors (Fig. 1a). We optimized our method by performing kinetics analysis and observed that immediate imaging post-coelenterazine injection (1 min post-rGluc injection with signal acquisition for 1 min) gave the highest signal reaching background level within 10 minutes (Fig. 1b–d) similar to our published work^{26,28–30}. Interestingly, no signal was detected after 10 minutes regardless of the tumor size (Fig. 1d). This indicates a fast assay turnover, allowing dynamic longitudinal monitoring of

Figure 2. Bioluminescence imaging of tumor vascularity and response to anti-angiogenic therapy. Mice were subcutaneously implanted with 10^6 U87-Fluc cells and one week later, randomized and treated with either vehicle (control) or tivozanib daily for 2 weeks ($n = 6$ /group). (a) Mice were imaged for tumor vascularity after injection of rGluc followed by coelenterazine. (b) Tumor volume was monitored after injection of D-luciferin, the Fluc substrate. A representative mouse from each group is shown. (c) Tumor size was measured weekly using a manual caliper and average fold changes in tumor size was calculated. (d) Tumor vascularity index (ratio of tumor rGluc signal to Fluc signal) was calculated at different time points. Results are represented as mean $\pm$ SD ($*P < 0.05$). (e) *Ex vivo* rGluc activity was analyzed in tumor homogenates using a luminometer after addition of coelenterazine. Results are represented as mean of rGluc activity in relative luminescence units (RLU) in tumor homogenates (normalized to total protein) $\pm$ S.D ($*P = 0.03$). (f) Mice from both groups were injected with Fluorescein-lectin and tumors were excised, sectioned and evaluated for Fluorescein (vascular endothelium) or immunostained with anti-CD31 antibody and analyzed by fluorescence microscopy. Scale bar, 50 μ m.

tumor vascularity at different time points without residual signal accumulation, concordant with the fast systemic clearance of Gluc (half-life < 20 min)²⁸. Further, necrotic tumors had a strong signal at their periphery and a weak to absent signal at their center (Fig. 1e). These results confirm that signals obtained within and around the tumor indeed reflect vascularity, since necrotic tumors are known to have numerous vessels at their growing rim and fewer feeding vessels in their core³⁵. Finally, we assessed the reproducibility of our assay by repeated imaging of the same tumor-bearing mice and observed similar signal with $< 12\%$ standard deviation among four different time points over 24 hrs (Fig. 1f).

We then explored if our method could assess tumor vasculature response to anti-angiogenic therapies. We engineered U87 cells to stably express firefly luciferase (U87-Fluc)²⁸. Fluc imaging here allows concomitant tumor size quantification with rGluc imaging of tumor vascularity. We implanted one million U87-Fluc cells subcutaneously into the flanks of nude mice and once tumors were formed (1 week post-implantation), mice were randomized into two groups; one group received oral anti-angiogenic therapy (1 mg/kg of tivozanib in DMSO/0.5% methylcellulose) while the control group received the drug vehicle (DMSO in 0.5% methylcellulose in water) daily for two weeks. We then applied our assay to evaluate tumor vascularity before and at different time-points post-treatment, by injecting rGluc (10 mg/kg body weight) followed by coelenterazine (5 mg/kg body weight) and imaging immediately over 1 minute. We observed a decrease in tumor-associated rGluc signal (vasculature) in the tivozanib-treated group, while it increased in control mice (Fig. 2a). To correlate these findings with tumor size, we concomitantly imaged the implanted tumors using Fluc-based bioluminescence imaging, which showed slower growth in the treated mice (Fig. 2b). These results were validated by weekly manual caliper measurements of tumor size in both groups (Fig. 2c). Since larger tumors are expected to have a richer vascular supply, we applied a tumor vascularity index to standardize the observed tumor vascularity to tumor size (rGluc/Fluc signal ratio). Calculation of the tumor vascularity index showed a significant ($p < 0.05$) decrease in the tivozanib-treated mice over time (Fig. 2d).

Figure 3. Toxicity analysis of rGluc tumor vascularity assay. (a) Mice weight from control and tivozanib-treated groups was monitored weekly. (b,c) Mice were injected with rGluc followed by coelenterazine for 2 weeks (3x/week) or PBS (control; $n = 3/\text{group}$). Blood samples were collected from both groups and analyzed for complete blood count and liver enzymes (b). Livers were collected, sectioned, and stained for Hematoxylin and Eosin (c). Shown is a representative liver section staining from each group. Scale bar, $20\mu\text{m}$.

We further validated our results with additional *ex vivo* experiments. Two weeks post-treatment, treated and control mice were injected with rGluc and one-minute later fresh tumors were excised, homogenized and analyzed for rGluc activity *ex vivo* using a luminometer. Consistent with our *in vivo* data, rGluc activity (normalized to total protein) was significantly (almost two folds; $P = 0.03$) decreased in the tivozanib-treated tumor homogenates (Fig. 2e). To further confirm these results, mice were injected with fluorescein lycopersicon esculentum (tomato) lectin (5 mg/kg body weight), an effective vascular endothelium marker in rodents. Mice were then perfused and tumors were resected, sectioned and analyzed by fluorescence microscopy. We observed that control tumor sections had a stronger fluorescein signal (therefore increased vascularity) as compared to tivozanib-treated tumors (Fig. 2f). We also stained these tumor sections for CD31, a known vessel-specific marker, and also observed a decrease in CD31 positivity in the tivozanib-treated group (Fig. 2f). All of these data demonstrate that systemically-injected rGluc indeed distribute in the tumor vasculature and can be used as a reporter to image tumor vascularity and its response to anti-angiogenic therapy, noninvasively and in real-time.

Finally, we evaluated potential cytotoxicity of repetitive injection of rGluc and coelenterazine. We weighed all mice weekly throughout the treatment duration and did not observe any changes in their weight (Fig. 3a). We also collected blood samples from both groups and analyzed them for liver enzymes and complete blood counts and again did not observe any major differences (Fig. 3b). Furthermore, Hematoxylin and Eosin staining on liver sections from both groups did not show any signs of toxicity (Fig. 3c). All together, these results suggest that tumor vascularity imaging using rGluc/coelenterazine does not lead to any toxicity in mice.

Conclusion

In this study, we describe a novel bioluminescent rGluc-based assay for non-invasive imaging and longitudinal monitoring of tumor vascularity and its response to anti-angiogenic therapy. To our knowledge, this is the first described method to use recombinant luciferase and bioluminescence imaging for this purpose. This method provides a simple, fast, sensitive, safe and cost-effective way to image tumor vascularity, response to therapeutics, and could be applied to different fields and diseases involving vascular processes.

Methods

Expression vectors. The firefly luciferase was previously cloned into a lentivirus vector under the control of the strong constitutive cytomegalovirus (CMV) promoter²⁸. Lentivirus vector stocks were produced by triple transfection of 293T cells (provided by Dr. Michele Calos, Stanford Univ. Sch. Med.) with the lentivirus vector plasmid, the packaging genome plasmid, pCMVΔR8.91, and the plasmid, pVSV-G (Clontech) encoding the vesicular stomatitis virus envelope glycoprotein as described³⁶. Vector stocks were used to transduce U87 glioblastoma cells (obtained from ATCC) with 20 transducing units (TU)/cell to produce U87-Fluc.

Tumor models. All animal studies were approved by the Subcommittee on Research Animal Care at the Massachusetts General Hospital and were performed in accordance to their guidelines and regulations. Athymic female nude mice were anesthetized with intraperitoneal (i.p) injection of ketamine (100 mg/kg) and xylazine (5 mg/kg). The skin was cleaned by scrubbing with 70% ethanol pads, followed by scrubbing with betadine pads. Different number of U87-Fluc cells in 50 μl PBS were pre-mixed with an equal volume of Matrigel (BD Bioscience) and implanted into the flanks of these mice.

In vivo bioluminescence imaging. Mice were anesthetized with isoflurane (Baxter) and the rGluc tumor vascularity assay was performed using *in vivo* bioluminescence imaging as follows: rGluc (10 mg/kg body weight; a kind gift from Dr. Bruce Bryan, Nanolight) was i.v. injected retro-orbitally followed (1 minute later) by the Gluc substrate coelenterazine (5 mg/kg body weight; Nanolight) and immediate acquisition of photon counts for 1 minute using the IVIS Spectrum Imaging System (PerkinElmer). Fluc imaging was performed in a similar way, 10 minutes after intraperitoneal (i.p) injection of 150 μl of D-Luciferin (4 mg/kg body weight) and recording photon counts using the IVIS Spectrum Imaging System. A light image of the animal was taken in the chamber using dim polychromatic illumination. Following data acquisition, post-processing and visualization was performed using either CMIR-Image, a program developed by the Center for Molecular Imaging Research using image display and analysis suite developed in IDL (Research Systems Inc., Boulder, CO; for Fig. 1a) or IVIS Spectrum image analysis. Regions of interest were defined using an automatic intensity contour procedure to identify bioluminescence signals with intensities significantly greater than the background. The mean, standard deviation, and sum of the photon counts in these regions were calculated as a measurement of rGluc or Fluc activity. For visualization purposes, bioluminescence images were fused with the corresponding white light surface images in a transparent pseudocolor overlay, permitting correlation of areas of bioluminescent activity with anatomy.

Ex vivo rGluc assay. Two weeks post-treatment, mice were injected with rGluc (10 mg/kg body weight) under deep anesthesia and one-minute later, tumors were removed and homogenized in 300 μl M-PER™ Mammalian Protein Extraction Reagent (Pierce) using a manual grinder. Total protein was quantified in the tumor homogenates using BSA standards. rGluc activity was then measured using the FlexStation 3 microplate reader (Molecular Devices) in 10 μl samples of tumor homogenates containing the same amount of total proteins by adding 90 μl coelenterazine (100 μM) in PBS-0.1% Triton X100 buffer.

Tumor/liver staining. Two weeks post-treatment, mice were i.v. injected with Fluorescein Lycopersicon Esculentum (Tomato) Lectin (5 mg/kg body weight; Vector Laboratories). Animals were sacrificed by transcardial perfusion with phosphate buffered saline (PBS) followed by 4% paraformaldehyde (PFA), under deep anesthesia with intraperitoneal (i.p) injection of ketamine (100 mg/kg) and xylazine (5 mg/kg). Tumors were collected, soaked in 30% sucrose overnight and sectioned into 7 μm sections. Sections were mounted on slides and evaluated for Fluorescein staining using fluorescence microscopy. Similarly, livers were removed, sectioned and stained with Hematoxylin and Eosin and analyzed by microscopy.

For CD31 tumor staining, sections were washed with PBS and nonspecific binding was blocked with 5% normal goat serum + 5% Rabbit serum + 2% BSA (Bovine Serum Albumin) in PBS-T (PBS 1x + Triton 0.3%), for 1 hour at room temperature. Sections were then incubated overnight at 4 °C with anti-CD31 antibody (Abcam; 1:50 dilution) in 2% BSA/PBS. Slides were washed several times with PBS-T and then incubated with anti-rabbit IgG – 647 Alexa (1:700 dilution in 2%BSA/PBS) for 1 hour at room temperature. Slides were rinsed with PBS-T followed with 50 mM NH₄Cl for 5 minutes to reduce the autofluorescence and then mounted on microscope slides with DAPI.

Statistical analysis. Comparisons of data were performed using a two-tailed Student's t test (unpaired) using Graphpad Prism 5. P values < 0.05 were considered significant.

References

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* **1**, 27–31 (1995).
2. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. *Nature* **407**, 249–257 (2000).
3. Shchorr, K. & Evan, G. Tumor angiogenesis: cause or consequence of cancer? *Cancer Res* **67**, 7059–7061 (2007).
4. Folkman, J. Tumor angiogenesis: therapeutic implications. *N Engl J M* **285**, 1182–1186 (1971).
5. Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. *J Clin Oncol* **31**, 2205–2218 (2013).
6. Bottsford-Miller, J. N., Coleman, R. L. & Sood, A. K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. *J Clin Oncol* **30**, 4026–4034 (2012).
7. Emblem, K. E. *et al.* Vessel caliber—a potential MRI biomarker of tumour response in clinical trials. *Nat rev. Clin oncol* **11**, 566–584 (2014).

8. Staton, C. A., Reed, M. W. & Brown, N. J. A critical analysis of current *in vitro* and *in vivo* angiogenesis assays. *Int J Exp Pathol* **90**, 195–221 (2009).
9. van der Bilt, A. R. *et al.* Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. *Clin cancer res: an official journal of the American Association for Cancer Research* **18**, 6306–6314 (2012).
10. Yang, G. *et al.* MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice. *Tumour Biol: the journal of the International Society for Oncodevelopmental Biology and Medicine* **36**, 3285–3291 (2015).
11. Beer, A. J. *et al.* Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin $\alpha(v)\beta(3)$ expression in man. *Clin Cancer Res* **12**, 3942–3949 (2006).
12. Haubner, R. *et al.* Noninvasive visualization of the activated $\alpha v\beta 3$ integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. *PLoS Med* **2**, e70 (2005).
13. Ma, T. *et al.* Serial *in vivo* imaging using a fluorescence probe allows identification of tumor early response to cetuximab immunotherapy. *Mol pharm* **12**, 10–17 (2015).
14. Sun, X. *et al.* Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin $\alpha v\beta 3$ and vascular endothelial growth factor. *Eur J Nucl Med Mol Imaging* **41**, 1428–1439 (2014).
15. Zhang, Y. *et al.* PET imaging of CD105/endothelin expression with a (6)(1)/(6)(4)Cu-labeled Fab antibody fragment. *Eur J Nucl Med Mol Imaging* **40**, 759–767 (2013).
16. Liu, Z. *et al.* Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. *J Nucl Med: official publication, Society of Nuclear Medicine* **55**, 818–823 (2014).
17. Wurdinger, T. *et al.* miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. *Cancer Cell* **14**, 382–393 (2008).
18. Arjaans, M. *et al.* Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. *Cancer Res* **73**, 3347–3355 (2013).
19. Jalali, S. *et al.* MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. *Neur Oncol* **16**, 868–879 (2014).
20. Rosen, B. R. *et al.* Susceptibility contrast imaging of cerebral blood volume: human experience. *Magn Reson Med* **22**, 293–299; discussion 300–293 (1991).
21. Rosen, B. R. *et al.* Contrast agents and cerebral hemodynamics. *Magn Reson Med* **19**, 285–292 (1991).
22. Hsu, Y. Y., Yang, W. S., Lim, K. E. & Liu, H. L. Vessel size imaging using dual contrast agent injections. *J Magn Reson Imaging: JMIR* **30**, 1078–1084 (2009).
23. Emblem, K. E. *et al.* Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. *Nat Med* **19**, 1178–1183 (2013).
24. Farrar, C. T. *et al.* Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. *PLoS one* **6**, e17228 (2011).
25. Waldman, A. D. *et al.* Quantitative imaging biomarkers in neuro-oncology. *Nat rev. Clin Oncol* **6**, 445–454 (2009).
26. Badr, C. E. & Tannous, B. A. Bioluminescence imaging: progress and applications. *Trends Biotechnol* **29**, 624–633 (2011).
27. Keyaerts, M., Caveliers, V. & Lahoutte, T. Bioluminescence imaging: looking beyond the light. *Trends Mol Med* **18**, 164–172 (2012).
28. Wurdinger, T. *et al.* A secreted luciferase for *ex vivo* monitoring of *in vivo* processes. *Nat Methods* **5**, 171–173 (2008).
29. Watts, J. C. *et al.* Bioluminescence imaging of A β deposition in bigenic mouse models of Alzheimer's disease. *Proc Natl Acad Sci USA* **108**, 2528–2533 (2011).
30. Luo, J., Lin, A. H., Masliah, E. & Wyss-Coray, T. Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration. *Proc Natl Acad Sci USA* **103**, 18326–18331 (2006).
31. Teng, J., Hejazi, S., Badr, C. E. & Tannous, B. A. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy. *Stem cells* **32**, 2021–2032 (2014).
32. Subleski, J. J. *et al.* Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy. *J Hepatol* **63**, 1181–1189 (2015).
33. Tannous, B. A. Gaussia luciferase reporter assay for monitoring biological processes in culture and *in vivo*. *Nat protoc* **4**, 582–591 (2009).
34. Tannous, B. A., Kim, D. E., Fernandez, J. L., Weissleder, R. & Breakefield, X. O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and *in vivo*. *Mol Ther* **11**, 435–443 (2005).
35. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. & Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. *Am J Pathol* **133**, 95–109 (1988).
36. Sena-Esteves, M., Tebbets, J. C., Steffens, S., Crombleholme, T. & Flake, A. W. Optimized large-scale production of high titer lentivirus vector pseudotypes. *J Virol Methods* **122**, 131–139 (2004).

Acknowledgements

This study was supported by grants from the National Institute of Health (NIH), the National Institute of Neurological disorders (NINDS) R01NS064983 and National Cancer Institute (NCI) R01CA166077 (BAT). The authors acknowledge the support from 1S10RR025504 Shared Instrumentation grant IVIS imaging system that was used to acquire imaging data, and the NIH/NINDS P30NS045776 (BAT) for the production of lentivirus vectors. The authors would also like to thank Dr. Bruce Bryan (Nanolight) for providing the recombinant Gluc protein.

Author Contributions

R.S.K., G.L., E.I.T., L.A.C. and G.K.L. conceived and performed experiments. R.S.K., G.L. and B.A.T. designed the study, analyzed data, and wrote the manuscript. B.A.T. provided funding and oversight for the project.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Kantar, R. S. *et al.* Imaging Tumor Vascularity and Response to Anti-Angiogenic Therapy Using Gaussia Luciferase. *Sci. Rep.* **6**, 26353; doi: 10.1038/srep26353 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>